fistulas (DAFs) and assessing maturation. We developed a DU simulator and used it to assess the accuracy of volume flow measurements.
Objective: Percutaneous access for endovascular aneurysm repair (P-EVAR) is less invasive compared with surgical access (S-EVAR). It is associated with shorter recovery and fewer wound complications. However, vascular closure devices (VCDs) are costly, and the economic impact of P-EVAR has important implications for resource allocation. The objective of our study was to determine the differences in cost between P-EVAR and S-EVAR.
Methods: We used a decision tree to analyze costs from a payer's perspective during the course of the index hospitalization. Probabilities, relative risks, and mean difference summary measures were obtained from a systematic review and meta-analysis. We modeled differences in surgical site infection, lymphocele, and length of hospitalization. Cost parameters were derived from the 2014 National Inpatient Sample using International Classification of Diseases, Ninth Revision, Clinical Modification codes. Attributable costs were estimated using generalized linear models adjusted by age, sex, and comorbidities. Sensitivity analysis was performed to determine the robustness of the results.
Results: A total of 6876 abdominal and thoracic EVARs were identified. P-EVAR resulted in a cost saving of $751 per procedure. The costs for P-EVAR were $1287 (95% confidence interval [CI] , $884-$1835), and the costs for S-EVAR were $2038 (95% CI, $757-$4280). P-EVARs were converted to open in 4.3% of cases. P-EVAR patients had a difference of À1.4 days (95% CI, À0.12 to À2.68) in length of hospitalization at a cost of $1190/day (standard error, $298). The cost saving of P-EVAR was primarily driven by the cost difference in length of hospitalization. In the base case, four VCDs were used per P-EVAR at $200/device. In the two-way sensitivity analysis, P-EVAR was cost saving even when 1.5 times more VCDs were used per procedure and the cost of each VCD was 1.5 times greater (Fig) . In our probabilistic sensitivity analysis, P-EVAR was the cost-saving strategy in 82.6% of 10,000 Monte Carlo simulations when simultaneously varying parameters across their uncertainty ranges.
Conclusions: P-EVAR had lower costs compared with S-EVAR and could result in dramatic cost savings if extrapolated to the number of aortic aneurysms repaired. Our analysis was a conservative estimate that does not account for the improved quality of life after P-EVAR.
Author Disclosures: J. C. Hong: Nothing to disclose; G. K. Yang: Nothing to disclose; B. A. Delarmente: Nothing to disclose; R. Khera: Nothing to disclose; J. Price: Nothing to disclose; J. C. Chen: Cook MedicaldCook Alpha post-market study, collaborator.
Cost-Effectiveness of Repeated Interventions on Failing Arteriovenous Fistulas: When Is It Time to Start Over?
Benjamin S. Brooke, Richard E. Nelson, Claire L. Griffin, Larry S. Kraiss. University of Utah School of Medicine, Salt Lake City, Utah
Objective: Arteriovenous fistulas (AVFs) used for hemodialysis commonly undergo multiple percutaneous and open interventions to maintain function patency, but it is unclear whether this strategy is The most cost-saving strategy is displayed across a range of model parameters. For example, in the base case (average patient), the cost per VCD was $200, and four devices were used per procedure, which lies in the blue area; therefore, percutaneous endovascular aneurysm repair (P-EVAR) is the most costsaving strategy.
cost-effective. The aim of this study was to evaluate the cost-effectiveness of performing repeated interventions vs starting a new AVF.
Methods: We reviewed all patients with mature radiocephalic, brachiocephalic, and brachiobasilic AVFs at a single academic institution between 2000 and 2016 and assessed open and percutaneous interventions to maintain functional patency after the fistula was created. These data were used to parameterize a Markov simulation model to determine the cost-effectiveness for performing an open or percutaneous intervention vs creating an AVF at a new anatomic location. This model compared strategies of creating a new AVF after the first to fourth reintervention within a 1-year time window, with the reference being creation of a new AVF on the fourth reintervention. We used this model to calculate incremental cost-effectiveness ratios (ICERs) using 2016 costs from Medicare's payer-perspective per quality-adjusted life-year (QALY) gained.
Results: A total of 720 mature AVFs were created during the 15-year period, and 283 (39%) underwent at least one intervention to maintain functional patency, with the median (interquartile range) time to first reintervention of 12.6 (10-17) months. For the strategies of creating a new AVF after the first vs the fourth reintervention, costs ranged from $672 to $846 for open procedures and $172 to $846 for percutaneous procedures (Table) . The ICERs for open interventions on failing AVFs were $154,273/QALY after the first reintervention and $59,917/QALY after the second reintervention, but creating a new AVF after the third open reintervention was dominated by other strategy and not cost-effective. The ICERs for percutaneous interventions on failing AVFs ranged from $574,494/QALY after the first reintervention to $203,946/QALY after the third reintervention (Table) .
Conclusions: Whereas the effectiveness of performing percutaneous interventions on failing AVFs diminishes after each reintervention, they are nevertheless less costly than creating a new AVF. In comparison, our data show that creating a new AVF is cost-effective after the second open reintervention procedure.
Author Disclosures: B. S. Brooke: Nothing to disclose; R. E. Nelson: Nothing to disclose; C. L. Griffin: Nothing to disclose; L. S. Kraiss: Nothing to disclose. Objective: Peripheral artery disease is a growing health care burden, with rising costs related to use of lower extremity revascularization (LER). We sought to examine recent trends in procedure volumes by level of disease, provider specialty, and encounter setting.
Lower Extremity Revascularization in the
Methods: The Medicare claims database was queried for 2012 and 2016 LER Current Procedural Terminology codes, and data were extracted for allowed charges, allowed claims, billing provider, and procedure place of service. We examined trends in procedure by level of arterial disease treated. The breakdown of endovascular procedures in 2012 was 36% angioplasty, 43% stenting, and 21% atherectomy. Of these, 9%, 11%, and 26%, respectively, were performed in an office-based setting. Comparatively in 2016, endovascular interventions were composed of 35% angioplasty, 36% stenting, and 29% atherectomy, of which 16%, 23%, and 51%, respectively, were performed in an office-based setting (P < .001). There was no significant change in iliac interventions during the time period; however, differences were pronounced at the infrainguinal level. Total femoropopliteal interventions were 101,071 (47%) in 2012 and 118,540 (47%) in 2016, with atherectomy increasing from 25,038 (25%) in 2012 to 37,453 (32%) in 2016 (Fig) . Total tibial endovascular interventions increased strikingly from 56,378 (23%) in 2012 to 79,333 (32%) in 2016, a relative volume increase of 41%. This was driven largely by increased use of tibial atherectomy, 19,008 (34%) in 2012 vs 34,438 (43%) in 2016 (P < .001). Notably, office-based procedures accounted for the bulk of the increase in atherectomy in 2016 (Fig) . In keeping with the trend, atherectomy performed on an "additional tibial vessel" increased from 3707 in 2012 to 6494 in 2016. These trends were consistent across all provider specialties.
Conclusions: Despite a lack of comparative evidence to support its use, the volume of office-based atherectomy procedures in the Medicare population continues to grow dramatically, particularly at the tibial level. These secular trends were similar across provider specialties and have significant cost implications.
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Financial Analysis of Fenestrated Endovascular Aortic Aneurysm Repair at a High-Volume Medical Center
Warren B. Chow, Denise M. Leverentz, Billi Tatum, Benjamin W. Starnes. University of Washington, Seattle, Wash
Objective: The objective of this study was to examine hospital finances and physician reimbursement associated with fenestrated endovascular aneurysm repair (FEVAR) for complex aortic disease at a high-volume aortic center. Costs and reimbursement for FEVAR were compared with those for open repair, and their trends were analyzed over time.
Methods: Clinical and financial data were retrospectively collected from electronic medical and administrative records. Data for each patient included inpatient and outpatient encounters 3 months before and 12 months after the index operation. 
